Literature DB >> 436336

IgG synthesis within the brain in multiple sclerosis and subacute sclerosing panencephalitis.

P W Ewan, P J Lachmann.   

Abstract

Intracerebral IgG synthesis was measured in patients with multiple sclerosis (MS), subacute sclerosing panencephalitis (SSPE) and in two control groups--patients with other neurological disorders and patients with non-neurological diseases. Significantly increased synthesis was found at all times in SSPE (P less than 0.001). Significantly elevated values were also found in MS (P less than 0.001), but in this group increased values were found mainly during relapse. These findings emphasize the immunological component in SSPE where there is known to be persistent measles virus infection in the brain, and in MS where the aetiology is unknown. Intracerebral IgG synthesis appears to be of diagnostic value in MS. The cerebrospinal fluid (CSF) IgG/total protein ratio was also measured in MS, and correlated only moderately well with the calculated IgG synthesis, indicating that the ratio provides a cruder estimate of intracerebral IgG synthesis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 436336      PMCID: PMC1537633     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Measles antibodies in multiple sclerosis.

Authors:  J M ADAMS; D T IMAGAWA
Journal:  Proc Soc Exp Biol Med       Date:  1962-12

2.  Measles-virus antibody and antigen in subacute sclerosing panencephalitis.

Authors:  J H Connolly; I V Allen; L J Hurwitz; J H Millar
Journal:  Lancet       Date:  1967-03-11       Impact factor: 79.321

Review 3.  Diagnosis and classification of multiple sclerosis.

Authors:  W I McDonald; A M Halliday
Journal:  Br Med Bull       Date:  1977-01       Impact factor: 4.291

4.  Recovery of Paramyxovirus from the jejunum of patients with multiple sclerosis.

Authors:  I Prasad; J D Broome; L P Pertschuk; J Gupta; A W Cook
Journal:  Lancet       Date:  1977-05-28       Impact factor: 79.321

5.  Isolation of measles virus from cell cultures of brain from a patient with subacute sclerosing panencephalitis.

Authors:  F E Payne; J V Baublis; H H Itabashi
Journal:  N Engl J Med       Date:  1969-09-11       Impact factor: 91.245

6.  Spinal fluid differences in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  H S Gutstein; S R Cohen
Journal:  Science       Date:  1978-01-20       Impact factor: 47.728

7.  Antibodies to oligodendroglia in patients with multiple sclerosis.

Authors:  O Abramsky; R P Lisak; D H Silberberg; D E Pleasure
Journal:  N Engl J Med       Date:  1977-12-01       Impact factor: 91.245

8.  Oligoclonal measles virus-specific IgG antibodies isolated from cerebrospinal fluids, brain extracts, and sera from patients with subacute sclerosing panencephalitis and multiple sclerosis.

Authors:  B Vandvik; E Norrby; H J Nordal; M Degré
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

9.  Jejunal immunopathology in amyotrophic lateral sclerosis and multiple sclerosis. Identification of viral antigens by immunofluorescence.

Authors:  L P Pertschuk; A W Cook; J K Gupta; J D Broome; J C Vuletin; D S Kim; D J Brigati; E A Rainford; F Nidsgorski
Journal:  Lancet       Date:  1977-05-28       Impact factor: 79.321

10.  Absence of measles-virus antigen in jejunum of multiple-sclerosis patients.

Authors:  J L Woyciechowska; D L Madden; J L Sever
Journal:  Lancet       Date:  1977-11-19       Impact factor: 79.321

View more
  10 in total

Review 1.  Immunopathogenesis of the neuropsychiatric manifestations of systemic lupus erythematosus.

Authors:  H G Bluestein; K D Pischel; V L Woods
Journal:  Springer Semin Immunopathol       Date:  1986

2.  Intraventricular interferon in a case of subacute sclerosing panencephalitis.

Authors:  A Boiardi; S M Baldini; A Sghirlanzoni; R Mancuso; F Corridori
Journal:  Ital J Neurol Sci       Date:  1987-06

3.  Measles antibodies, kappa-lambda light chain distribution and immunoglobulins in serum, cerebrospinal fluid and brain of a patient affected with multiple sclerosis.

Authors:  F Bollengier; A Mahler; G Clinet
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

4.  Cerebrospinal fluid IgG changes in subacute sclerosing panencephalitis in the various stages of the disease and during isoprinosine therapy.

Authors:  M Poloni; B Rocchelli; G Lanzi; F Rosano Burgio; D Besana
Journal:  Ital J Neurol Sci       Date:  1981-05

5.  Cellular and humoral immunity in subacute sclerosing panencephalitis.

Authors:  S S Dhib-Jalbut; A M Abdelnoor; F S Haddad
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

6.  CFS oligoclonal bands in MS and other neurological diseases detected by agarose isoelectric focusing and electrophoresis.

Authors:  D Cerrato; A Salmaggi; C Ariano; L La Mantia; A Nespolo
Journal:  Ital J Neurol Sci       Date:  1984-09

7.  Immune complexes in serum and in cerebrospinal fluid in African trypanosomiasis. Correlation with polyclonal B cell activation and with intracerebral immunoglobulin synthesis.

Authors:  P H Lambert; M Berney; G Kazyumba
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

8.  Murine V lambda x and V lambda x-containing antibodies bind human myelin basic protein.

Authors:  F S Galin; C C Maier; S R Zhou; J N Whitaker; J E Blalock
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

9.  Intracerebral synthesis of antibodies to measles and distemper viruses in patients with subacute sclerosing panencephalitis and multiple sclerosis.

Authors:  N T Gorman; J Habicht; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1980-01       Impact factor: 4.330

10.  Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides.

Authors:  Michael Graner; Tiffany Pointon; Sean Manton; Miyoko Green; Kathryn Dennison; Mollie Davis; Gino Braiotta; Julia Craft; Taylor Edwards; Bailey Polonsky; Anthony Fringuello; Timothy Vollmer; Xiaoli Yu
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.